MET233 and MET097

Phase 2

PFIZER (PFE)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q1 '27

PFEPhase 2$143.7B

MET233 and MET097 Phase 2 Est. Readout

MET233 and MET097• Obesity and Obesity-related Medical Conditions132

Q1 2027~QConfirmed

CT.gov

00%

Sep '26

PFEPhase 2$143.7B

MET233 and MET097 Phase 2 Est. Readout

MET233 and MET097• Obesity and Obesity-related Medical Conditions381

Sep 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Obesity and Obesity-related Medical Conditions

View Full Landscape

Drug Information

Target Indication

Obesity and Obesity-related Medical Conditions

Clinical Trial

NCT06924320

Last updated: 3/4/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

PFE

PFIZER

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

13 valent pneumococcal conjugate vaccine with Polysorbate 80Phase 3

Vaccines, Pneumococcal

Insulin LisproPhase 3

Diabetes Mellitus

Cyclosporine APhase 3

Renal Transplantation

DVS-233 SR (desvenlafaxine sustained release )Phase 3

Major Depressive Disorder

MeropenemPhase 3

Complicated Intra-abdominal Infections

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts